Research Analysts Offer Predictions for PAHC FY2026 Earnings

Phibro Animal Health Corporation (NASDAQ:PAHC) – Investment analysts at Zacks Research upped their FY2026 earnings per share estimates for shares of Phibro Animal Health in a research note issued on Wednesday, April 8th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $2.99 for the year, up from their previous estimate of $2.98. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2026 earnings at $0.67 EPS, Q1 2027 earnings at $0.78 EPS, Q2 2027 earnings at $0.79 EPS, Q4 2027 earnings at $0.79 EPS, FY2027 earnings at $3.07 EPS and FY2028 earnings at $3.18 EPS.

Several other equities research analysts have also recently weighed in on the company. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a report on Friday, February 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Phibro Animal Health currently has a consensus rating of “Moderate Buy” and an average price target of $37.50.

Phibro Animal Health Trading Up 0.7%

NASDAQ PAHC opened at $59.09 on Thursday. Phibro Animal Health has a fifty-two week low of $16.16 and a fifty-two week high of $59.67. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. The stock has a 50 day simple moving average of $51.87 and a two-hundred day simple moving average of $44.31. The stock has a market cap of $2.39 billion, a P/E ratio of 26.26, a price-to-earnings-growth ratio of 0.90 and a beta of 0.69.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The business had revenue of $373.91 million during the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Phibro Animal Health by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock valued at $57,519,000 after purchasing an additional 13,884 shares during the period. State Street Corp lifted its stake in shares of Phibro Animal Health by 5.4% in the 4th quarter. State Street Corp now owns 942,279 shares of the company’s stock valued at $35,204,000 after purchasing an additional 48,243 shares during the period. Millennium Management LLC increased its position in Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after buying an additional 626,492 shares in the last quarter. Geode Capital Management LLC increased its position in Phibro Animal Health by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock valued at $21,265,000 after buying an additional 21,951 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Phibro Animal Health by 1.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock valued at $18,394,000 after buying an additional 6,826 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Insider Activity at Phibro Animal Health

In other news, CEO Jack Bendheim sold 110,842 shares of the firm’s stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $48.38, for a total value of $5,362,535.96. Following the completion of the transaction, the chief executive officer owned 122,958 shares in the company, valued at $5,948,708.04. This trade represents a 47.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders sold 316,259 shares of company stock valued at $15,256,865. Company insiders own 50.13% of the company’s stock.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th were paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Wednesday, March 4th. Phibro Animal Health’s dividend payout ratio (DPR) is presently 21.33%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.